High-risk strains of human papillomavirus (HPV), such as HPV 16, are causative agents in most cases of human cervical carcinoma. Worldwide, this disease is responsible for approximately 370,000 newly diagnosed cases each year, with about a 50% mortality rate. HPV 16, as well as other """"""""high risk"""""""" strains, codes for two oncogenes, E6 and E7. E7 functions by binding to and inactivating Rb, while E6 is best known for its ability to mediate the rapid degradation of p53. The accumulating evidence, however, indicates that this is not the only function of E6, and indeed, cannot completely explain its transforming potential. Previous work in our laboratory has shown that transfection of the E6 gene from HPV 16 into a number of cell lines, derived from two species and several tissue types, protects them from TNF-triggered apoptosis in a p53-independent manner. E6 was then shown to bind to TNF R1, resulting in impaired transmission of the apoptotic signal. Recently, we have found that E6 binds to FADD as well as to TNF R1, and can block apoptosis mediated by Fas as well as that mediated by TNF R1. This project integrates a variety of biochemical, genetic and cell biological approaches designed to achieve our overall goal of understanding the interactions of E6 with host apoptotic pathways at a molecular level, and of laying the groundwork for future novel therapeutic interventions. Specifically, four specific aims will address the following questions.1) What region(s) of TNF R1 are required for binding to E6? 2) What is the biological significance of E6-mediated protection from TNF in the contexts of virus survival and oncogenicity? 3) How generalized is the protection from apoptotic stimuli provided by HPV 16 E6? 4) What molecules can block this protective ability? The ability of papillomavirus-encoded proteins to interact with key regulators in receptor-triggered apoptotic pathways has not previously been described, and may contribute to the ability of the virus to evade the host immune system and/or to transform cells. A more complete understanding of such interactions will, therefore, enhance efforts to develop novel and effective preventive and therapeutic approaches to papillomavirus infection. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA095461-05
Application #
7256460
Study Section
Virology Study Section (VR)
Program Officer
Read-Connole, Elizabeth Lee
Project Start
2003-09-01
Project End
2008-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
5
Fiscal Year
2007
Total Cost
$273,418
Indirect Cost
Name
Loma Linda University
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
009656273
City
Loma Linda
State
CA
Country
United States
Zip Code
92350
Filippova, Maria; Evans, Whitney; Aragon, Robert et al. (2014) The small splice variant of HPV16 E6, E6, reduces tumor formation in cervical carcinoma xenografts. Virology 450-451:153-164
Williams, Vonetta M; Filippova, Maria; Filippov, Valery et al. (2014) Human papillomavirus type 16 E6* induces oxidative stress and DNA damage. J Virol 88:6751-61
Yuan, Chung-Hsiang; Filippova, Maria; Tungteakkhun, Sandy S et al. (2012) Small molecule inhibitors of the HPV16-E6 interaction with caspase 8. Bioorg Med Chem Lett 22:2125-9
Haynes, Teka-Ann S; Filippov, Valery; Filippova, Maria et al. (2012) DNA damage induces down-regulation of UDP-glucose ceramide glucosyltransferase, increases ceramide levels and triggers apoptosis in p53-deficient cancer cells. Biochim Biophys Acta 1821:943-53
Whitaker, Erin L; Filippov, Valery; Filippova, Maria et al. (2011) Splice variants of mda-7/IL-24 differentially affect survival and induce apoptosis in U2OS cells. Cytokine 56:272-81
Williams, Vonetta M; Filippova, Maria; Soto, Ubaldo et al. (2011) HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol 6:45-57
Tungteakkhun, Sandy S; Filippova, Maria; Fodor, Nadja et al. (2010) The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain. J Virol 84:1453-63
Filippova, Maria; Filippov, Valery A; Kagoda, Mercy et al. (2009) Complexes of human papillomavirus type 16 E6 proteins form pseudo-death-inducing signaling complex structures during tumor necrosis factor-mediated apoptosis. J Virol 83:210-27
Tungteakkhun, Sandy S; Filippova, Maria; Neidigh, Jonathan W et al. (2008) The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain. J Virol 82:9600-14
Filippov, Valery; Schmidt, Erin L; Filippova, Maria et al. (2008) Splicing and splice factor SRp55 participate in the response to DNA damage by changing isoform ratios of target genes. Gene 420:34-41

Showing the most recent 10 out of 18 publications